| Description | FMK-MEA is a potent and selective p90 Ribosomal S6 Kinase (RSK) inhibitor. |
| In vitro | FMK-MEA treatment inhibits RSK2 kinase activity in diverse, highly invasive human cancer cell lines including 212LN, M4e, A549, and SKBR3 cells.?Treatment with the RSK-specific inhibitor FMK-MEA significantly attenuates RSK2 activity, as assessed by the phosphorylation levels of Ser-386 and the consequent invasive ability of A549 cells.FMK-MEA is a water-soluble derivative of fmk. |
| In vivo | FMK-MEA treatment has no effect on the tumor size, and the proliferation rate of the primary tumor.FMK-MEA treatment (80 mg/kg/day for 16 days by intraperitoneal injection) in highly metastatic M4e cell xenograft nude mice results in a significant attenuation of LN metastasis. |
| molecular weight | 399.46 |
| Molecular formula | C21H26FN5O2 |
| CAS | 1414811-15-6 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. Li D, et al. The prometastatic ribosomal S6 kinase 2-cAMP response element-binding protein (RSK2-CREB) signaling pathway up-regulates the actin-binding protein fascin-1 to promote tumor metastasis. J Biol Chem. 2013 Nov 8;288(45):32528-38. |